Skip to main content
Premium Trial:

Request an Annual Quote

Bruker and Charles River Ink Deal to Link MALDI Biotyper and Accugenix Database

Premium

Bruker and Charles River said this week they have agreed to a partnership deal under which they will sell Bruker's MALDI Biotyper system packaged with access to Charles River's cGMP-compliant Accugenix microbial database.

Called the Axcess System, the new product is aimed at environmental monitoring applications and will allow Biotyper customers to "have access to the most current and validated database for identifications, saving time and costs associated with validating library releases," the companies said.

Charles River will also provide sequence-based identifications of organisms that are not identified by the Biotyper, reducing customers' needs for secondary systems. The product is intended for use in markets including the pharmaceutical, biopharmaceutical, personal care, and other manufacturing industries, the companies said.

"With Charles River products in virtually every pharmaceutical microbiology laboratory, we are looking forward to working with Charles River to expand our efforts to make the MALDI Biotyper the new standard in microbial identification for industrial microbiology,” Gary Kruppa, Bruker's vice president of business development, said in a statement.

Launched by Bruker in 2006, the MALDI Biotyper identifies bacteria by matching their protein fingerprints against fingerprints contained in Bruker's proprietary database. The company has installed more than 800 of the devices worldwide.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.